Reaction
Product Storage Issue reporting signals
As of the last recalculation, Product Storage Issue appears in 1,779 FAERS reports alongside 14 co-occurring drug terms. The strongest observed disproportionality signal is INSULIN GLARGINE (PRR 43.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Insulin Glargine | 611 | 43.6 | 43.7 |
| Guselkumab | 98 | 33.9 | 34.0 |
| Oral Semaglutide | 62 | 10.2 | 10.2 |
| Belimumab | 25 | 9.4 | 9.4 |
| Pancrelipase | 27 | 8.3 | 8.3 |
| Tirzepatide | 95 | 7.2 | 7.2 |
| Abatacept | 80 | 7.0 | 7.0 |
| Insulin Glargine-Yfgn | 13 | 7.0 | 7.0 |
| Insulin Lispro | 65 | 5.7 | 5.7 |
| Budesonide, Glycopyrrolate, And Formoterol Fumarate | 4 | 4.5 | 4.5 |
| Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate | 12 | 3.4 | 3.4 |
| Abaloparatide | 8 | 3.2 | 3.2 |
| Bimekizumab | 4 | 2.2 | 2.2 |
| Dupilumab | 71 | 1.8 | 1.8 |